Navigation Links
John Theurer Cancer Center first in New Jersey to offer complete capabilities of Provenge
Date:4/4/2011

HACKENSACK, N.J. (April 4, 2011) The John Theurer Cancer Center at Hackensack University Medical is the only cancer center in New Jersey where advanced prostate cancer patients can receive a cell collection process and infusion of Provenge (Sipuleucel-T). Now, patients can find the complete capabilities of this breakthrough immunotherapy in one center led by one physician.

"We are now able to provide patients with care that is not only innovative for improved outcomes, but convenient and more personal," said Robert Alter, M.D., Co-Chief, Urologic Oncology at the John Theurer Cancer Center. "Throughout the Provenge delivery process, patients are treated by a single team of our expert staff, allowing for a more intimate, comforting course of treatment."

Provenge is the first autologous cellular immunotherapy available for the treatment of advanced prostate cancer, meaning it is designed to use cells from a patient's own immune system to identify and target prostate cancer. The John Theurer Cancer Center participated in the Provenge clinical trials, and began prescribing and infusing patients when the treatment was approved in June 2010. This February, the John Theurer Cancer Center received approval by Provenge manufacturer, Dendreon, to conduct leukapheresis, a cell collection process vital for the development of the immunotherapy.

"Provenge is another example of the cutting-edge treatments we provide our patients at the John Theurer Cancer Center," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., Chief Innovations Officer and Professor and Vice President of Cancer Services at the John Theurer Cancer Center. "We strive to deliver patients with the latest treatment options and state-of-the-art technology in order to deliver exceptional care."

Provenge treatment at the John Theurer Cancer Center begins with leukapheresis, a cell collection process administered by a clinical assistant. The patient's cells are sent to a Provenge manufacturing facility, where they are combined with a protein that is found in most prostate cancers linked to an immune stimulating agent. The dose of Provenge is then sent back to the cancer center for infusion. This whole process is performed three times over approximately six weeks for complete treatment.


'/>"/>

Contact: Jaymie DeGaetano
jaymie.degaetano@widmeyer.com
646-213-7243
John Theurer Cancer Center
Source:Eurekalert

Related medicine news :

1. The MMRF and John Theurer Cancer Center to host patient symposium
2. John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques
3. John Theurer Cancer Center to host Eighth Annual Northern New Jersey Breast Cancer Conference
4. Oncology basic research director at John Theurer Cancer Center continues transplantation research
5. John Theurer Cancer Center presents studies on promising therapies for aggressive blood cancers
6. The John Theurer Cancer Center to unveil 40 presentations at the 52nd ASH Annual Meeting
7. John Theurer Cancer Center to present innovative research at 2 surgical meetings
8. John Theurer Cancer Center first cancer center in N.J. to acquire new radiotherapy system
9. John Theurer Cancer Center and LLS host panel discussion with leading hematologists
10. The John Theurer Cancer Center recognizes medical physics team for safety track record
11. John Theurer Cancer Center experts present new cancer research at ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2017)... Illinois (PRWEB) , ... May 28, 2017 , ... ... , a medical scrubs and uniform distributor based in Lima, Ohio. The sale began ... features approximately one million units of medical garments, scrubs, uniforms, and medical accessories, including ...
(Date:5/27/2017)... California (PRWEB) , ... May 26, 2017 , ... A ... citizens who visit a doctor for colds or respiratory issues that are not responsive ... excessive time pressure on doctors may be largely responsible for the problem both in ...
(Date:5/27/2017)... ... May 27, 2017 , ... Most us are familiar with the ... study from the Osteoarthritis Initiative shows that certain people who experience consistent ... in advance may give doctors the opportunity to treat patients before the problem becomes ...
(Date:5/26/2017)... Fairfax, VA (PRWEB) , ... May 26, 2017 ... ... is pleased to announce a new educational seminar to focus on current legislative ... Regulatory News(LEARN) seminar will begin at 1 p.m. Sunday, Sept. 10, and will ...
(Date:5/26/2017)... , ... May 26, 2017 , ... ... delicatessen foods, is sharing bold recipes for Memorial Day entertaining that are sure ... , “Boar’s Head fresh sliced meats and cheeses featured in these refreshingly ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... , May 10, 2017 Global Health ... Latin America , published its 2017 ranking ... ranking is based on extensive data analysis from GHI,s ... largest hospitals database for the region. The GHI database covers ... , offering more than 130 data points for each institution ...
(Date:5/9/2017)...  Demonstrating its commitment to representing research- based ... Pharmaceutical Research and Manufacturers of America (PhRMA) today ... now have to meet new research and development ... join PhRMA. "By putting in place ... clear message that being a member of PhRMA ...
(Date:5/6/2017)... , May 5, 2017   Provista , a ... more than 200,000 customers, today announced Jim Cunniff ... wealth of executive and business experience to Provista, including most ... pharmacy in California . He assumed his ... "Jim is a great fit for Provista," says Jody ...
Breaking Medicine Technology: